NCT03966443Recruiting
Fluciclovine PET/CT in Multiple Myeloma Patients
PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose
Source: ClinicalTrials.gov · Last updated 30 May 2019 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 10 (estimated)
- First submitted
- 27 May 2019
- Start date
- 1 Mar 2019
- Primary completion date
- 31 Jan 2020
- Lead sponsor
- Oslo University Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT03966443
What you commit to
- Study type: Observational
- Planned participants: 10
- From 1 Mar 2019 to the primary completion date, 31 Jan 2020
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients with contraindications to ASCT treatment
Who the study is looking for
- Multiple myeloma patients suitable for ASCT treatment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oslo University Hosptal Coordinator of this site? Confirm its status | Oslo | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.